Latest & greatest articles for hypertension

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hypertension

1. Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy

pulmonary hypertension (CTEPH) after pulmonary endarterectomy (PEA). Objectives: This study sought to assess the safety and efficacy of PADN using remote magnetic navigation in patients with residual CTEPH after PEA. Methods: Fifty patients with residual CTEPH despite medical therapy at least 6 months after PEA, who had mean pulmonary artery pressure ≥25 mm Hg or pulmonary vascular resistance (PVR) > 400 dyn‧s‧cm -5 based on right heart catheterization were randomized to treatment with PADN (PADN group (...) Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get

2020 EvidenceUpdates

2. Hypertension - Diagnosis and Management

hypertension refers to the untreated condition in which BP is elevated in the office but is normal when measured by ambulatory blood pressure monitoring (ABPM), home blood pressure measurement (HBPM), or both. Masked hypertension refers to untreated patients in whom the BP is normal in the office but is elevated when measured by HBPM or ABPM. Classification Based on the average BP recorded, hypertension is classified as High-Normal, Stage 1, Stage 2, or Stage 3 (Note: Figure 1 lists MOBP values only (...) device is recommended in patients with regular heart rate. [ Strong Recommendation, Strong Evidence ] Hypertension is diagnosed in adults when automated office blood pressure reading is ≥ 135/85 in the higher BP arm. [ Strong Recommendation, Strong Evidence ] When a manual office blood pressure device (MOBP) is used hypertension is diagnosed at ≥ 140/90. [ Strong Recommendation, Strong Evidence ] Consider 24-hour ambulatory blood pressure monitoring, or standardized home blood pressure monitoring

2020 Clinical Practice Guidelines and Protocols in British Columbia

3. Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis Full Text available with Trip Pro

and objective: Controversy has arisen in the scientific community on whether the use of renin-angiotensin system (RAS) inhibitors in the context of COVID-19 would be beneficial or harmful. A meta-analysis of eligible studies comparing the occurrence of severe and fatal COVID-19 in infected hypertensive patients who were under treatment with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) vs no treatment or other antihypertensives was conducted. Methods: PubMed, Google (...) Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19

2020 EvidenceUpdates

4. CCS/CTS Position Statement on Pulmonary Hypertension Full Text available with Trip Pro

Thoracic Society clinical practice guideline update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2019; 3 : 177-198 Figure 1 An algorithm for the work-up of pulmonary hypertension (PH). ABG, arterial blood gas; CHD, congenital heart disease; CT, computed tomography; CTD, connective tissue disease; CTEPH, chronic thromboembolic pulmonary hypertension; DLCO, diffusion capacity of the lung for carbon monoxide; ECG, electrocardiogram; HR-CT, high-resolution computed tomography; mPAP (...) these modalities, particularly at high pulmonary artery pressure (PAP), and estimation of RA pressure according to inferior vena cava size and collapsibility is sometimes inaccurate. Fisher M.R. Forfia P.R. Chamera E. et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179 : 615-621 , Rich J.D. Shah S.J. Swamy R.S. Kamp A. Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients

2020 Canadian Cardiovascular Society

5. Diagnosis of hypertension using ambulatory blood pressure monitoring in patients with clinic blood pressure ? 140/90mmHg and ? 180/110mmHg

Diagnosis of hypertension using ambulatory blood pressure monitoring in patients with clinic blood pressure ? 140/90mmHg and ? 180/110mmHg 1 Public Summary Document Application No. 1572 – Diagnosis of hypertension using ambulatory blood pressure monitoring in patients with clinic blood pressure = 140/90mmHg and = 180/110mmHg Applicant: High Blood Pressure Research Council of Australia Inc. Date of MSAC consideration: MSAC 78 th Meeting, 3 April 2020 Context for decision: MSAC makes its advice (...) to comparative safety, clinical effectiveness and cost-effectiveness, MSAC supported MBS funding of diagnosis of hypertension using ambulatory blood pressure monitoring (ABPM) in patients with clinic blood pressure =140/90 mmHg and =180/110 mmHg on the basis that ABPM is the accepted gold standard for the diagnosis of high blood pressure in primary care. MSAC accepted that ABPM was cost-effective, but advised that the proposed fee should not include the cost of the consumables. MSAC was concerned

2020 Medical Services Advisory Committee

6. Pulmonary arterial hypertension: sometimes drug-induced

of fenfluramine and dexfenfluramine, and implicated many other amphetamines. In 2016, 1,273 observations of pulmonary arterial hypertension attributed to benfluorex were reported to the French Health Products Agency. The number of drugs known to provoke pulmonary arterial hypertension has increased over the years. These include anti-tumour treatments such as dasatinib or related drugs, immunosuppressants such as leflunomide or omalizumab and various other drugs such as interferons or sofosbuvir. The disorders (...) sometimes improve with withdrawal from the drug responsible. When pulmonary arterial hypertension is suspected to be the cause of respiratory disorders, it can be of great help to patients to consider the possibility that it was induced by a drug. ©Prescrire 1 July 2020 Source: "Drug-induced pulmonary arterial hypertension" Prescrire International 2020; 29 (217): 180-183. Subscribers only. Enjoy full access to Prescrire International, and support independent information Share See also: "Methylphenidate

2020 Prescrire

7. Gestational Hypertension and Preeclampsia

% of maternal deaths, whereas in Africa and Asia they contribute to 9% of deaths. Although maternal mortality is much lower in high-income countries than in developing countries, 16% of maternal deaths can be attributed to hypertensive disorders . In the United States, the rate of preeclampsia increased by 25% between 1987 and 2004 . Moreover, in comparison with women giving birth in 1980, those giving birth in 2003 were at 6.7-fold increased risk of severe preeclampsia . This complication is costly: one (...) Magnesium Concentration and Toxicities Table 3. Antihypertensive Agents Used for Urgent Blood Pressure Control in Pregnancy ACOG Family of Sites ACOG Family of Sites American College of Obstetricians and Gynecologists 409 12th Street SW, Washington, DC 20024-2188 Copyright 2020. All rights reserved. | Please Confirm Bulk pricing was not found for item. Please try reloading page. Price Member Price

2020 American College of Obstetricians and Gynecologists

8. Maternal cardiovascular risk after hypertensive disorder of pregnancy

Maternal cardiovascular risk after hypertensive disorder of pregnancy Maternal Cardiovascular Risk After Hypertensive Disorder of Pregnancy - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged (...) Actions . 2020 May 13;heartjnl-2020-316541. doi: 10.1136/heartjnl-2020-316541. Online ahead of print. Maternal Cardiovascular Risk After Hypertensive Disorder of Pregnancy , , , , , , , , Affiliations Expand Affiliations 1 Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. 2 Cardiometabolic, George Institute for Global Health, Sydney, New South Wales, Australia. 3 Sydney Medical School, University of Sydney, Sydney, NSW, Australia. 4 Medicine, University of New South Wales

2020 EvidenceUpdates

9. Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children

, angiotensin converting enzyme inhibitor; AHA-ACC, American Heart Association-American College of Cardiology; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; DBP, diastolic blood pressure; ESH, European Society of Hypertension; HBPM, home blood pressure monitoring; SBP, systolic blood pressure. Table 6. Blood pressure thresholds for diagnosis of resistant hypertension Description BP threshold Diabetes Systolic BP> 130 mm Hg or diastolic BP> 80 mm Hg High cardiovascular (...) 25, 2019. After the discussions, the guidelines were further revised and ?nalized for anelectronic vote by all 81 members of the HCGC, with > 70% support required for approval of each new guideline. Guidelines for the diagnosis, assessment, prevention, and treatment of hyper- tension in adults and children are published separately. 10 Key Messages Resistant hypertension (RHT) is de?ned as blood pressure (BP) above target despite 3 or more BP- lowering drugs at optimal doses preferably including

2020 CPG Infobase

10. The Diagnosis and Management of Hypertension in the Primary Care Setting

The Diagnosis and Management of Hypertension in the Primary Care Setting Diagnosis and Management of Hypertension (HTN) in Primary Care (2020) - VA/DoD Clinical Practice Guidelines Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through (...) the submenu options to access/activate the submenu links. Get help from Veterans Crisis Line Locator Contact Search Contact Us Locator Get help from Veterans Crisis Line Search Enter your search text Button to start search More VA More VA Inside VA Budget and Performance Inside the Media Room National Observances Special Events » » » » » Diagnosis and Management of Hypertension (HTN) in Primary Care (2020) VA/DoD Clinical Practice Guidelines Menu Menu Quick Links Enter ZIP code here Enter ZIP code here

2020 VA/DoD Clinical Practice Guidelines

11. Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial. (Abstract)

Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial. Deprescribing of antihypertensive medications is recommended for some older patients with polypharmacy and multimorbidity when the benefits of continued treatment may not outweigh the harms.This study aimed to establish whether antihypertensive medication reduction is possible without significant changes (...) in systolic blood pressure control or adverse events during 12-week follow-up.The Optimising Treatment for Mild Systolic Hypertension in the Elderly (OPTIMISE) study was a randomized, unblinded, noninferiority trial conducted in 69 primary care sites in England. Participants, whose primary care physician considered them appropriate for medication reduction, were aged 80 years and older, had systolic blood pressure lower than 150 mm Hg, and were receiving at least 2 antihypertensive medications were

2020 JAMA

12. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. (Abstract)

Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Catheter-based renal denervation has significantly reduced blood pressure in previous studies. Following a positive pilot trial, the SPYRAL HTN-OFF MED (SPYRAL Pivotal) trial was designed to assess the efficacy of renal denervation in the absence of antihypertensive medications.In this international, prospective, single (...) -blinded, sham-controlled trial, done at 44 study sites in Australia, Austria, Canada, Germany, Greece, Ireland, Japan, the UK, and the USA, hypertensive patients with office systolic blood pressure of 150 mm Hg to less than 180 mm Hg were randomly assigned 1:1 to either a renal denervation or sham procedure. The primary efficacy endpoint was baseline-adjusted change in 24-h systolic blood pressure and the secondary efficacy endpoint was baseline-adjusted change in office systolic blood pressure from

2020 Lancet

13. Epoprostenol for pulmonary arterial hypertension

Epoprostenol for pulmonary arterial hypertension 1 Driving better decision-making in healthcare Epoprostenol for treating pulmonary arterial hypertension Technology Guidance from the MOH Drug Advisory Committee Published on 1 April 2020 Guidance recommendations The Ministry of Health’s Drug Advisory Committee has recommended: ? ? epoprostenol (Veletri) 1.5 mg powder for solution for infusion for treating idiopathic or heritable pulmonary arterial hypertension (PAH) or PAH associated (...) Committee (“the Committee”) considered the evidence presented for the technology evaluation of epoprostenol (Veletri) for pulmonary arterial hypertension (PAH). The Agency for Care Effectiveness conducted the evaluation in consultation with clinical experts from public healthcare institutions. Published clinical and economic evidence for epoprostenol was considered in line with its registered indication. The Committee acknowledged that another brand of epoprostenol (Flolan) is available in Singapore

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

14. Treprostinil (Trepulmix) - chronic thromboembolic pulmonary hypertension (CTEPH)

(treprostinil) An overview of Trepulmix and why it is authorised in the EU What is Trepulmix and what is it used for? Trepulmix is a medicine for use in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH), a condition linked with high blood pressure in the lungs caused by blood clots. It can be used to improve the capacity for physical activity in patients: • who cannot have an operation for treating the condition; • whose condition remains or continues to return after an operation (...) that widens blood vessels and stops platelets (blood components) from sticking to each other to form blood clots. In patients with CTEPH, these effects of treprostinil prevent blood clots and lower blood pressure in the pulmonary artery and so improve symptoms of the disease. What benefits of Trepulmix have been shown in studies? A main study involving 105 patients with severe CTEPH who could not have an operation found that Trepulmix can improve patients’ capacity for physical activity, measured

2020 European Medicines Agency - EPARs

15. A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease

. Methods: To investigate whether distal diuretics are noninferior to dietary sodium restriction in reducing BP in patients with CKD stage G3 or G4 and hypertension, we conducted a 6-week, randomized, open-label crossover trial comparing amiloride/hydrochlorothiazide (5 mg/50 mg daily) with dietary sodium restriction (60 mmol per day). Antihypertension medication was discontinued for a 2-week period before randomization. We analyzed effects on BP, kidney function, and fluid balance and related (...) hyponatremia. Conclusions: Distal diuretics are noninferior to dietary sodium restriction in reducing BP and extracellular volume in CKD. Diuretic sensitivity in CKD is maintained despite lower diuretic clearance. Clinical trial registry name and registration number: DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease (DD), . Keywords: chronic kidney disease; clinical hypertension; clinical trial; diuretics; pharmacokinetics; water-electrolyte balance. Copyright © 2020

2020 EvidenceUpdates

16. Management of hypertension evidence map

Management of hypertension evidence map application/vnd.ms-excel.sheet.macroEnabled.12

2020 Public Health Wales Observatory Evidence Service

17. A Community-Based Intervention for Managing Hypertension in Rural South Asia. Full Text available with Trip Pro

). The intervention involved home visits by trained government community health workers for blood-pressure monitoring and counseling, training of physicians, and care coordination in the public sector. A total of 2645 adults with hypertension were enrolled. The primary outcome was reduction in systolic blood pressure at 24 months. Follow-up at 24 months was completed for more than 90% of the participants.At baseline, the mean systolic blood pressure was 146.7 mm Hg in the intervention group and 144.7 mm Hg (...) A Community-Based Intervention for Managing Hypertension in Rural South Asia. The burden of hypertension is escalating, and control rates are poor in low- and middle-income countries. Cardiovascular mortality is high in rural areas.We conducted a cluster-randomized, controlled trial in rural districts in Bangladesh, Pakistan, and Sri Lanka. A total of 30 communities were randomly assigned to either a multicomponent intervention (intervention group) or usual care (control group

2020 NEJM

18. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations

-selective NSAID plus a proton pump inhibitor (PPI), or a selective cyclo-oxygenase-2 (COX-2) inhibitor should be used; for those with a high risk of peptic ulcer disease, a selective COX-2 inhibitor plus PPI are needed. For patients with pre-existing hypertension receiving renin-angiotensin system blockers, empirical addition (or increase in the dose) of an antihypertensive agent of a different class should be considered. Blood pressure and renal function should be monitored in most cases. Conclusion (...) -resistant hypertension, high risk of cardiovascular disease and severe chronic kidney disease (CKD). Before treatment with a NSAID is started, blood pressure should be measured, unrecognised CKD should be screened in high risk cases, and unexplained iron-deficiency anaemia should be investigated. For patients with high cardiovascular risk, and if NSAID treatment cannot be avoided, naproxen or celecoxib are preferred. For patients with a moderate risk of peptic ulcer disease, monotherapy with a non

2020 EvidenceUpdates

19. Pregnancy Health: Exercise Programs to Prevent Gestational Hypertension

excessive weight gain and prevent gestational diabetes ( ). This systematic review assessed the effectiveness of exercise programs in preventing gestational hypertensive disorders, defined as new onset high blood pressure during pregnancy. There are four different types of gestational hypertensive disorders: chronic hypertension, gestational hypertension, preeclampsia, and preeclampsia superimposed on chronic hypertension (Vest et al., 2014). This CPSTF finding is specific to one type—gestational (...) hypertension without the development of preeclampsia-eclampsia. Summary of Results Detailed results from the systematic review are available in the . The systematic review and meta-analysis included 17 randomized controlled trials. Compared to interventions without an exercise program or to usual care, exercise programs reduced the development of high blood pressure during pregnancy by 46% (17 studies) Additional analyses of a subset of 16 studies showed the following: The cesarean delivery rate

2020 Community Preventive Services Task Force

20. Essential Hypertension

. Reversible Causes of Sustained Elevated Blood Pressure Readings Medications: • NSAIDs * • oral contraceptive agents • glucocorticoid or mineralocorticoid steroids * interferes with antihypertensive medications Medications (continued): • appetite suppressants • anti-depressants • MAO inhibitors • cyclosporine • erythropoietin Lifestyle factors • alcohol > 2 drinks/day • sedentary lifestyle Illicit drugs • cocaine • amphetamines • anabolic steroids Diet • High sodium (esp. elderly or African-American (...) 2003; 362:759. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008;51:960-969. The 7th report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 2003; 42:1206. Complete report: NHLBI, 2004, NIH Publication No 04-5230. UMHS Hypertension Guideline, May 2014 16 APPENDIX. Standardized Blood Pressure Measurement Types of Measuring Devices • Aneroid manometer could be used. However

2020 University of Michigan Health System